ArticleACS omega2025
Electrospun Tenofovir/Emtricitabine-Zein Nanofibers for Pre-Exposure Prophylaxis Platform against HIV through Vaginal Delivery.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human immunodeficiency virus (HIV) remains a major global public health concern, particularly affecting vulnerable populations. Pre-exposure prophylaxis (PrEP) using tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) is a strategy recommended by the World Health Organization to prevent sexual transmission of HIV. Vaginal delivery systems based on nanofibers offer several advantages, including high surface area, mucoadhesiveness, and controlled drug release. This study aimed to develop and characterize TDF and FTC-loaded zein-based electrospun nanofibers for vaginal PrEP. Electrospun hybrid nanofibers were produced using zein in combination with mucoadhesive polymers such as polyvinylpyrrolidone (PVP) and poly-(ethylene oxide) (PEO). The nanofibers were characterized by Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and scanning electron microscopy (SEM). Mechanical strength and mucoadhesive properties were evaluated for vaginal use. In vitro release of TDF and FTC from the nanofibers was also investigated. The ZK7-TF formulation showed 898.048 ± 300.838 nm uniform diameters and porosity 60.03%. Mucoadhesion work reached 0.121 ± 0.014 mJ·cm
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.